{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:03:18Z","timestamp":1784214198134,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11669-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:04:43Z","timestamp":1784210683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis, and biological characterization of a hydrophobic tagging EGFR degrader for the treatment of non-small-cell lung cancer"],"prefix":"10.1007","author":[{"given":"Mo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotianyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"1","key":"11669_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"11669_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou F, Guo H, Xia Y et al (2025) The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol 22(2):95\u2013116. https:\/\/doi.org\/10.1038\/s41571-024-00971-2","journal-title":"Nat Rev Clin Oncol"},{"key":"11669_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107895","volume":"194","author":"M Wespiser","year":"2024","unstructured":"Wespiser M, Swalduz A, P\u00e9rol M (2024) Treatment sequences in EGFR mutant advanced NSCLC. Lung Cancer 194:107895. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107895","journal-title":"Lung Cancer"},{"issue":"3","key":"11669_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169\u2013181. https:\/\/doi.org\/10.1038\/nrc2088","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"11669_CR5","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms222312828","volume":"22","author":"WL Cheng","year":"2021","unstructured":"Cheng WL, Feng PH, Lee KY et al (2021) The role of EREG\/EGFR pathway in tumor progression. Int J Mol Sci 22(23):12828. https:\/\/doi.org\/10.3390\/ijms222312828","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11669_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15\u201331. https:\/\/doi.org\/10.1517\/14728222.2011.648617","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"11669_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ (2022) Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol 19(8):499\u2013514. https:\/\/doi.org\/10.1038\/s41571-022-00639-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"11669_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nrc1506","volume":"4","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer 4(12):956\u2013965. https:\/\/doi.org\/10.1038\/nrc1506","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"11669_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2025.2481392","volume":"40","author":"D Zhang","year":"2025","unstructured":"Zhang D, Zhao J, Yang Y et al (2025) Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future. J Enzyme Inhib Med Chem 40(1):2481392. https:\/\/doi.org\/10.1080\/14756366.2025.2481392","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"18","key":"11669_CR10","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","volume":"29","author":"JB Blaquier","year":"2023","unstructured":"Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, Recondo G (2023) Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer. Clin Cancer Res 29(18):3579\u20133591. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1912","journal-title":"Clin Cancer Res"},{"issue":"21","key":"11669_CR11","doi-asserted-by":"publisher","first-page":"14276","DOI":"10.1021\/acs.jmedchem.2c01159","volume":"65","author":"D Sun","year":"2022","unstructured":"Sun D, Zhang J, Dong G, He S, Sheng C (2022) Blocking non-enzymatic functions by PROTAC-mediated targeted protein degradation. J Med Chem 65(21):14276\u201314288. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01159","journal-title":"J Med Chem"},{"issue":"1","key":"11669_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 7(1):113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"11669_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai JM, Nowak RP, Ebert BL, Fischer ES (2024) Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol 25(9):740\u2013757. https:\/\/doi.org\/10.1038\/s41580-024-00729-9","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"11669_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale B, Cheng M, Park KS, Kaniskan H\u00dc, Xiong Y, Jin J (2021) Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer 21(10):638\u2013654. https:\/\/doi.org\/10.1038\/s41568-021-00365-x","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"11669_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21(3):181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"11669_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 16(2):101\u2013114. https:\/\/doi.org\/10.1038\/nrd.2016.211","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"11669_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","volume":"63","author":"M Cheng","year":"2020","unstructured":"Cheng M, Yu X, Lu K et al (2020) Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders. J Med Chem 63(3):1216\u20131232. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01566","journal-title":"J Med Chem"},{"key":"11669_CR18","doi-asserted-by":"publisher","DOI":"10.1039\/d5md01113b","author":"A Kumar","year":"2020","unstructured":"Kumar A, Sharma V, Kumari P, Kaur R, Bhatia R (2020) PROTAC approaches against drug-resistant EGFRC797S\/L858R\/T790M mutants: biological evaluation and SAR studies (2020-2025). RSC Med Chem. https:\/\/doi.org\/10.1039\/d5md01113b","journal-title":"RSC Med Chem"},{"issue":"14","key":"11669_CR19","doi-asserted-by":"publisher","first-page":"14569","DOI":"10.1021\/acs.jmedchem.5c00693","volume":"68","author":"X Wang","year":"2025","unstructured":"Wang X, Wang C, Ma Y et al (2025) Discovery of a novel EGFR PROTAC degrader against C797S resistance mutation with potent antitumor efficacy in NSCLC treatment. J Med Chem 68(14):14569\u201314593. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00693","journal-title":"J Med Chem"},{"issue":"1","key":"11669_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1080\/14756366.2022.2062338","volume":"37","author":"M O Aboelez","year":"2022","unstructured":"O Aboelez M, Belal A, Xiang G, Ma X (2022) Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M. J Enzyme Inhib Med Chem 37(1):1196\u20131211. https:\/\/doi.org\/10.1080\/14756366.2022.2062338","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11669_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108864","volume":"164","author":"L Li","year":"2025","unstructured":"Li L, Li Y, Ma X et al (2025) A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation. Bioorg Chem 164:108864. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108864","journal-title":"Bioorg Chem"},{"issue":"2","key":"11669_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","volume":"10","author":"A Pike","year":"2026","unstructured":"Pike A, Lee ECY, Michaelides IN et al (2026) Lessons learned in linking PROTACs from discovery to the clinic. Nat Rev Chem 10(2):117\u2013132. https:\/\/doi.org\/10.1038\/s41570-025-00784-6","journal-title":"Nat Rev Chem"},{"issue":"8","key":"11669_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nchembio.597","volume":"7","author":"TK Neklesa","year":"2011","unstructured":"Neklesa TK, Tae HS, Schneekloth AR et al (2011) Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat Chem Biol 7(8):538\u2013543. https:\/\/doi.org\/10.1038\/nchembio.597","journal-title":"Nat Chem Biol"},{"key":"11669_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115741","volume":"260","author":"Q He","year":"2023","unstructured":"He Q, Zhao X, Wu D et al (2023) Hydrophobic tag-based protein degradation: development, opportunity and challenge. Eur J Med Chem 260:115741. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115741","journal-title":"Eur J Med Chem"},{"issue":"15","key":"11669_CR25","doi-asserted-by":"publisher","first-page":"15579","DOI":"10.1021\/acs.jmedchem.5c00488","volume":"68","author":"S Xie","year":"2025","unstructured":"Xie S, Zhu J, Zhan F et al (2025) Overcoming E3 ligase-mediated resistance: development of novel hydrophobic tagging-based degraders targeting ALK protein. J Med Chem 68(15):15579\u201315597. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00488","journal-title":"J Med Chem"},{"key":"11669_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116345","volume":"270","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Li J, Shen S et al (2024) Targeting EGFR degradation by autophagosome degraders. Eur J Med Chem 270:116345. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116345","journal-title":"Eur J Med Chem"},{"issue":"10","key":"11669_CR27","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.1021\/acs.jmedchem.4c00128","volume":"67","author":"Z Yang","year":"2024","unstructured":"Yang Z, Liu Z, Wan S et al (2024) Discovery of novel small-molecule-based potential PD-L1\/EGFR dual inhibitors with high druggability for glioblastoma immunotherapy. J Med Chem 67(10):7995\u20138019. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00128","journal-title":"J Med Chem"},{"issue":"23","key":"11669_CR28","doi-asserted-by":"publisher","first-page":"21344","DOI":"10.1021\/acs.jmedchem.4c02273","volume":"67","author":"L Ma","year":"2024","unstructured":"Ma L, Zhang K, Huang Z et al (2024) Development of novel silicon-based hydrophobic tags (SiHyT) for targeted proteins degradation. J Med Chem 67(23):21344\u201321363. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02273","journal-title":"J Med Chem"},{"key":"11669_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108876","volume":"164","author":"J Zhu","year":"2025","unstructured":"Zhu J, Zhan F, Xie J et al (2025) Development of adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor activities. Bioorg Chem 164:108876. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108876","journal-title":"Bioorg Chem"},{"issue":"7","key":"11669_CR30","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1021\/acs.jmedchem.2c02045","volume":"66","author":"M Wang","year":"2023","unstructured":"Wang M, Lin R, Li J et al (2023) Discovery of LL-K8-22: a selective, durable, and small-molecule degrader of the CDK8-cyclin C complex. J Med Chem 66(7):4932\u20134951. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02045","journal-title":"J Med Chem"},{"key":"11669_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118121","volume":"300","author":"W Tao","year":"2025","unstructured":"Tao W, Zhu J, Fu Z et al (2025) Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging. Eur J Med Chem 300:118121. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118121","journal-title":"Eur J Med Chem"},{"issue":"14","key":"11669_CR32","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.1039\/d2cs00339b","volume":"51","author":"KM Riching","year":"2022","unstructured":"Riching KM, Caine EA, Urh M, Daniels DL (2022) The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. Chem Soc Rev 51(14):6210\u20136221. https:\/\/doi.org\/10.1039\/d2cs00339b","journal-title":"Chem Soc Rev"},{"issue":"1","key":"11669_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-06036-6","volume":"83","author":"G Jendrisek","year":"2026","unstructured":"Jendrisek G, Mesa D, Conte A, Malabarba MG, Sigismund S (2026) Beyond the membrane: rethinking EGFR signaling in physiology and cancer. Cell Mol Life Sci 83(1):109. https:\/\/doi.org\/10.1007\/s00018-025-06036-6","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"11669_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1248\/bpb.b23-00924","volume":"47","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Takahashi JI, Sakurai H (2024) New directions for advanced targeting strategies of EGFR signaling in cancer. Biol Pharm Bull 47(5):895\u2013903. https:\/\/doi.org\/10.1248\/bpb.b23-00924","journal-title":"Biol Pharm Bull"},{"issue":"19","key":"11669_CR35","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1002\/1878-0261.13229","volume":"16","author":"AS Hatat","year":"2022","unstructured":"Hatat AS, Benoit-Pilven C, Pucciarelli A et al (2022) Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer. Mol Oncol 16(19):3490\u20133508. https:\/\/doi.org\/10.1002\/1878-0261.13229","journal-title":"Mol Oncol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11669-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11669-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11669-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:04:43Z","timestamp":1784210683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11669-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":35,"alternative-id":["11669"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11669-1","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no declared conflicts of interest, financial relationships, or personal affiliations that may have biased the results presented in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}